On November 10th of last year, RudaCure was finally selected for the Korea Health Industry Development Institute's Early Startup Package Support Project and will receive support for the commercialization of RCI001 until May 2021.
Through this project, the company will more thoroughly prepare for clinical trials and lay the groundwork for FDA clinical trials.